- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01437540
Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Long-Term, Randomized, Study of the Safety and Tolerability of a Fixed-Dose Combination of Aclidinium Bromide/Formoterol Fumarate Compared With Formoterol Fumarate in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Forest Investigative Site 1162
-
Birmingham, Alabama, United States, 35209
- Forest Investigative Site 1493
-
Birmingham, Alabama, United States, 35235
- Forest Investigative Site 1620
-
Mobile, Alabama, United States, 36608
- Forest Investigative Site 1127
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Forest Investigative Site 1613
-
Peoria, Arizona, United States, 85381
- Forest Investigative Site 1623
-
Phoenix, Arizona, United States, 85018
- Forest Investigative Site 1379
-
Phoenix, Arizona, United States, 85012
- Forest Investigative Site 1582
-
Phoenix, Arizona, United States, 85020
- Forest Investigative Site 1581
-
Phoenix, Arizona, United States, 85050
- Forest Investigative Site 1571
-
-
Arkansas
-
Fort Smith, Arkansas, United States, 72901
- Forest Investigative Site 1596
-
-
California
-
Encinitas, California, United States, 92024
- Forest Investigative Site 1547
-
Lakewood, California, United States, 90712
- Forest Investigative Site 1088
-
Los Angeles, California, United States, 90025
- Forest Investigative Site 1624
-
Los Angeles, California, United States, 90048
- Forest Investigative Site 1927
-
Paramount, California, United States, 90723
- Forest Investigative Site 1388
-
San Diego, California, United States, 92128
- Forest Investigative Site 1503
-
Torrance, California, United States, 90505
- Forest Investigative Site 1374
-
Vista, California, United States, 92083
- Forest Investigative Site 1331
-
Walnut Creek, California, United States, 94598
- Forest Investigative Site 2039
-
-
Colorado
-
Boulder, Colorado, United States, 80304
- Forest Investigative Site 1597
-
Colorado Springs, Colorado, United States, 80907
- Forest Investigative Site 1137
-
Denver, Colorado, United States, 80206
- Forest Investigative Site 0892
-
Fort Collins, Colorado, United States, 80528
- Forest Investigative Site 2037
-
Wheat Ridge, Colorado, United States, 80033
- Forest Investigative Site 1327
-
Wheat Ridge, Colorado, United States, 80033
- Forest Investigative Site 2045
-
-
Connecticut
-
Norwalk, Connecticut, United States, 06851
- Forest Investigative Site 1589
-
Stamford, Connecticut, United States, 06902
- Forest Investigative Site 1598
-
-
Florida
-
Brandon, Florida, United States, 33511
- Forest Investigative Site 1154
-
Brandon, Florida, United States, 33511
- Forest Investigative Site 1944
-
Clearwater, Florida, United States, 33765
- Forest Investigative Site 1152
-
Debary, Florida, United States, 32713
- Forest Investigative Site 1617
-
Debary, Florida, United States, 32713
- Forest Investigative Site 1959
-
Edgewater, Florida, United States, 32132
- Forest Investigative Site 1516
-
Hollywood, Florida, United States, 33024
- Forest Investigative Site 1403
-
Orlando, Florida, United States, 32822
- Forest Investigative Site 1556
-
Ormond Beach, Florida, United States, 32174
- Forest Investigative Site 1542
-
Pensacola, Florida, United States, 32504
- Forest Investigative Site 0974
-
Tampa, Florida, United States, 33613
- Forest Investigative Site 2047
-
Venice, Florida, United States, 34292
- Forest Investigative Site 1565
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Forest Investigative Site 0980
-
Atlanta, Georgia, United States, 30329
- Forest Investigative Site 1851
-
Atlanta, Georgia, United States, 30342
- Forest Investigative Site 1567
-
Lawrenceville, Georgia, United States, 30046
- Forest Investigative Site 1607
-
-
Illinois
-
O'Fallon, Illinois, United States, 62269
- Forest Investigative Site 1409
-
River Forest, Illinois, United States, 60305
- Forest Investigative Site 2051
-
Springfield, Illinois, United States, 62702
- Forest Investigative Site 1604
-
-
Indiana
-
Evansville, Indiana, United States, 47713
- Forest Investigative Site 1576
-
-
Iowa
-
Council Bluffs, Iowa, United States, 51503
- Forest Investigative Site 1549
-
-
Kentucky
-
Bowling Green, Kentucky, United States, 42101
- Forest Investigative Site 2033
-
Crescent Springs, Kentucky, United States, 41017
- Forest Investigative Site 2085
-
Louisville, Kentucky, United States, 40215
- Forest Investigative Site 1336
-
-
Louisiana
-
Lafayette, Louisiana, United States, 70503
- Forest Investigative Site 2024
-
New Orleans, Louisiana, United States, 70115
- Forest Investigative Site 1430
-
Sunset, Louisiana, United States, 70584
- Forest Investigative Site 1360
-
-
Maine
-
Auburn, Maine, United States, 04210
- Forest Investigative Site 1566
-
-
Maryland
-
Baltimore, Maryland, United States, 21236
- Forest Investigative Site 1333
-
Columbia, Maryland, United States, 21044
- Forest Investigative Site 1622
-
Towson, Maryland, United States, 21204
- Forest Investigative Site 1590
-
-
Massachusetts
-
Fall River, Massachusetts, United States, 02720
- Forest Investigative Site 1570
-
Haverhill, Massachusetts, United States, 01830
- Forest Investigative Site 1546
-
North Dartmouth, Massachusetts, United States, 02747
- Forest Investigative Site 1029
-
Worcestor, Massachusetts, United States, 01605
- Forest Investigative Site 1595
-
-
Michigan
-
Traverse City, Michigan, United States, 49684
- Forest Investigative Site 1605
-
-
Minnesota
-
Fridley, Minnesota, United States, 55432
- Forest Investigative Site 1527
-
Minneapolis, Minnesota, United States, 55407
- Forest Investigative Site 1124
-
Plymouth, Minnesota, United States, 55441
- Forest Investigative Site 1619
-
-
Missouri
-
Chesterfield, Missouri, United States, 63017
- Forest Investigative Site 1587
-
Jefferson City, Missouri, United States, 65109
- Forest Investigative Site 1572
-
St. Louis, Missouri, United States, 63141
- Forest Investigative Site 1399
-
St. Louis, Missouri, United States, 63141
- Forest Investigative Site 1599
-
-
Montana
-
Bozeman, Montana, United States, 59718
- Forest Investigative Site 1831
-
Missoula, Montana, United States, 59808
- Forest Investigative Site 1400
-
-
Nebraska
-
Bellevue, Nebraska, United States, 68123
- Forest Investigative Site 1609
-
Lincoln, Nebraska, United States, 68506
- Forest Investigative Site 1616
-
Omaha, Nebraska, United States, 68134
- Forest Investigative Site 1615
-
-
Nevada
-
Las Vegas, Nevada, United States, 89183
- Forest Investigative Site 1562
-
-
New Hampshire
-
Rochester, New Hampshire, United States, 03867
- Forest Investigative Site 1610
-
-
New Jersey
-
Brick, New Jersey, United States, 08723
- Forest Investigative Site 1558
-
Cherry Hill, New Jersey, United States, 08003
- Forest Investigative Site 1559
-
Ocean, New Jersey, United States, 07712
- Forest Investigative Site 1394
-
Summit, New Jersey, United States, 07901
- Forest Investigative Site 2084
-
-
New York
-
Brooklyn, New York, United States, 11229
- Forest Investigative Site 0972
-
New York, New York, United States, 10028
- Forest Investigative Site 1425
-
New York, New York, United States, 10016
- Forest Investigative Site 1163
-
Newburgh, New York, United States, 12550
- Forest Investigative Site 1554
-
Syracuse, New York, United States, 13210
- Forest Investigative Site 1563
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27612
- Forest Investigative Site 1557
-
Shelby, North Carolina, United States, 28152
- Forest Investigative Site 1588
-
Wilmington, North Carolina, United States, 28401
- Forest Investigative Site 1553
-
Winston-Salem, North Carolina, United States, 27103
- Forest Investigative Site 1550
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Forest Investigative Site 1134
-
Cincinnati, Ohio, United States, 45242
- Forest Investigative Site 2028
-
Cincinnati, Ohio, United States, 45224
- Forest Investigative Site 1594
-
Marion, Ohio, United States, 43302
- Forest Investigative Site 1541
-
Toledo, Ohio, United States, 43608
- Forest Investigative Site 1530
-
Zanesville, Ohio, United States, 43701
- Forest Investigative Site 1393
-
-
Oregon
-
Ashland, Oregon, United States, 97520
- Forest Investigative Site 1612
-
Corvallis, Oregon, United States, 97330
- Forest Investigative Site 1575
-
Eugene, Oregon, United States, 97404
- Forest Investigative Site 1081
-
Portland, Oregon, United States, 97213
- Forest Investigative Site 1580
-
Portland, Oregon, United States, 97220
- Forest Investigative Site 1552
-
-
Pennsylvania
-
Beaver, Pennsylvania, United States, 15009
- Forest Investigative Site 1574
-
Beaver, Pennsylvania, United States, 15009
- Forest Investigative Site 1577
-
Bethlehem, Pennsylvania, United States, 18020
- Forest Investigative Site 1126
-
Erie, Pennsylvania, United States, 16506
- Forest Investigative Site 1423
-
Hershey, Pennsylvania, United States, 17033
- Forest Investigative Site 1504
-
Pittsburgh, Pennsylvania, United States, 15243
- Forest Investigative Site 1146
-
Pittsburgh, Pennsylvania, United States, 15213
- Forest Investigative Site 1569
-
Pittsburgh, Pennsylvania, United States, 15236
- Forest Investigative Site 1548
-
Pittsburgh, Pennsylvania, United States, 15243
- Forest Investigative Site 1560
-
Tipton, Pennsylvania, United States, 16684
- Forest Investigative Site 1449
-
Uniontown, Pennsylvania, United States, 15401
- Forest Investigative Site 1564
-
-
Rhode Island
-
Johnston, Rhode Island, United States, 02919
- Forest Investigative Site 1144
-
-
South Carolina
-
Charleston, South Carolina, United States, 29406
- Forest Investigative Site 2072
-
Easley, South Carolina, United States, 29640
- Forest Investigative Site 1568
-
Greenville, South Carolina, United States, 29615
- Forest Investigative Site 1506
-
Greer, South Carolina, United States, 29651
- Forest Investigative Site 1601
-
Spartanburg, South Carolina, United States, 29303
- Forest Investigative Site 0900
-
Union, South Carolina, United States, 29379
- Forest Investigative Site 1450
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57702
- Forest Investigative Site 1365
-
-
Texas
-
Arlington, Texas, United States, 76012
- Forest Investigative Site 1440
-
Austin, Texas, United States, 78731
- Forest Investigative Site 1954
-
Dallas, Texas, United States, 75231
- Forest Investigative Site 1155
-
Dallas, Texas, United States, 75231
- Forest Investigative Site 1328
-
El Paso, Texas, United States, 79903
- Forest Investigative Site 1332
-
Fort Worth, Texas, United States, 76104
- Forest Investigative Site 2012
-
Killeen, Texas, United States, 76543
- Forest Investigative Site 1902
-
San Antonio, Texas, United States, 78215
- Forest Investigative Site 1498
-
San Antonio, Texas, United States, 78228
- Forest Investigative Site 1614
-
San Antonio, Texas, United States, 78229
- Forest Investigative Site 1906
-
San Antonio, Texas, United States, 78229
- Forest Investigative Site 2004
-
-
Utah
-
Magna, Utah, United States, 84044
- Forest Investigative Site 1600
-
-
Virginia
-
Abingdon, Virginia, United States, 24210
- Forest Investigative Site 1480
-
Alexandria, Virginia, United States, 22304
- Forest Investigative Site 1579
-
-
Washington
-
Spokane, Washington, United States, 99216
- Forest Investigative Site 1573
-
Spokane, Washington, United States, 99204
- Forest Investigative Site 1142
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Current or former cigarette smokers with a cigarette smoking history of at least 10 pack-years
- A diagnosis of stable moderate to severe COPD and stable airway obstruction as defined by the Global Initiative for Chronic Obstructive Lung Disease guidelines and stable airway obstruction.
Exclusion Criteria:
- Patients who have been hospitalized for an acute COPD exacerbation within three months prior to Visit 1
- Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the six weeks before Visit 1.
- Patients with any clinically significant respiratory conditions other than COPD
- Clinical history that suggests that the patient has asthma as opposed to COPD
- Chronic use of oxygen therapy ≥ 15 hours/day
- Patients with clinically significant cardiovascular conditions
- Patients with uncontrolled infection that may place the patient at risk resulting from human immunodeficiency virus (HIV), active hepatitis and/or patients with diagnosed active tuberculosis
- Patients with a history of hypersensitivity reaction to inhaled anticholinergics,
- Patients with Stage II hypertension, defined as systolic pressure of 160 and above, and/or diastolic pressure of 100 and above
- Current diagnosis of cancer other than basal or squamous cell skin cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: 1
Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg fixed dose combination (FDC), high dose twice per day
|
Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
|
|
Active Comparator: 2
Inhaled formoterol fumarate 12 μg, twice per day
|
Inhaled formoterol fumarate 12 μg, twice per day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Patients to Experience at Least One Treatment-emergent Adverse Event (TEAE)
Time Frame: Up to study Week 56 ± 3 days
|
TEAEs were coded Version 16.0 of the Medical Dictionary for Regulatory Activities (MedDRA)
|
Up to study Week 56 ± 3 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Patients to Experience Any Potentially Clinically Significant (PCS) Post-baseline Change in Clinical Laboratory Values for Hematology, Chemistry or Urinalysis at the End of the Study
Time Frame: Up to study Week 52
|
<0.85 x lower limit of normal (LLN) or > 1.15 upper limit of normal (ULN) for hemoglobin, hematocrit, red blood cell, platelet, white blood cell, neutrophil and lymphocyte counts >1.15 × ULN for eosinophil, basophil and monocyte counts >1.15 x ULN for aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma glutamyl transferase, total bilirubin, creatinine kinase, lactate dehydrogenase, blood urea nitrogen, creatinine, uric acid, total cholesterol, triglycerides <0.85 x LLN or >1.15 ULN for fasting glucose, calcium, phosphorus, total protein and albumin <0.95 x LLN or >1.05 x ULN for sodium, potassium and chloride Urinary blood, ketones or pH <0.85 x LLN or > 1.15 ULN |
Up to study Week 52
|
|
Percentage of Patients to Experience a Potentially Clinically Significant (PCS) Change in Pulse Rate, Systolic and Diastolic Blood Pressure
Time Frame: Up to study Week 56 ± 3 days
|
Systolic BP ≥180 mmHg and increase ≥20 mmHg from baseline or ≤90 mmHg and decrease ≥20 mmHg from baseline; Diastolic BP ≥105 mmHg and increase ≥15 mmHg from baseline or ≤50 mmHg and decrease ≥15 mmHg from baseline; Pulse rate ≥ 110 bpm and increase ≥ 15% from baseline or ≤ 50 bpm and decrease ≥15% from baseline
|
Up to study Week 56 ± 3 days
|
|
Percentage of Patients to Experience Potentially Clinically Significant Changes in ECG From Baseline
Time Frame: Up to study Week 56 ± 3 days
|
Potentially clinically significant changes were defined as listed in the table below for QT interval, QTcB, QTcF, QRS interval, PR interval and heart rate (HR)
|
Up to study Week 56 ± 3 days
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Anticonvulsants
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Bromides
- Formoterol Fumarate
Other Study ID Numbers
- LAC-MD-32
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
University of LeicesterUniversity Hospitals, Leicester; University of StrathclydeRecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway DiseaseUnited Kingdom
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
Strados Labs, Inc.WithdrawnChronic Obstructive Pulmonary Disease (COPD)United States
-
Pulmatrix Inc.CompletedChronic Obstructive Pulmonary Disease (COPD)United Kingdom
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease (COPD)United States
Clinical Trials on Aclidinium Bromide/Formoterol Fumarate
-
AstraZenecaCompletedChronic Obstructive Pulmonary DiseaseUnited States, Australia, Canada, New Zealand
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Sweden, Ukraine, United Kingdom
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Russian Federation, Australia, Czech Republic, Poland
-
AstraZenecaCompletedChronic Obstructive Pulmonary DiseaseUnited States, Australia, Canada, New Zealand
-
Daewoong Pharmaceutical Co. LTD.Completed
-
AstraZenecaParexelCompletedCOPDPhilippines, Vietnam, China, Taiwan, India
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Germany, Czech Republic, France, Hungary, Italy, Peru, Poland, Russian Federation, South Africa, Spain, Ukraine
-
University of DundeeAstraZeneca; NHS TaysideCompletedChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
AstraZenecaCompletedChronic Obstructive Pulmonary DiseaseUnited States, Canada
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD)Belgium, Germany